Treatment of Rheumatoid Arthritis in Combined Therapy with MethotrexateSylejman Rexhepi, Gani Dragusha, Mjellma Rexhepi, Ejup Pllana, Vjollca Sahatçiu-Meka, Masar Gashi, Hajrije Hundozi-Hysenaj, Sadik Llullaku.
In 2 years study, at Rheumatologic Department of University Clinic Centre in Pristina, it was done application of combined therapy with Methotrexate (tablets Methotrexate of 15 mg weekly, Sulphasalazine 2g daily, Hydroxychloroquine 400 mg) to patients with rheumatoid arthritis. Methods: During our investigation were treated 20 patients, 18 females and 2 males, in the treated group with Methotrexate, and 20 patients 16 female and 4 male in treated group with Methotrexate (MTX), Sulphasalazine (SSZ) and Hydroxychloroquine (HCQ). The diagnosis of rheumatoid arthritis was concluded on diagnostic criteria of American Rheumatism Association (ARA). The aim of this study is to compare medical results between group I (with tablets Methotrexate), as simple therapy and group II (with MTX, SSZ and HCQ), as combined therapy of drugs that modify rheumatic diseases (DMARDs), according to laboratory analysis, subjective and objective parameters, as well as side effects of drugs that were used. During application of DMARDs we were based on principals of drug applications. Results: To the investigated patients of group I and II that were of ages (23â72 years old vs. 21-69 years old) with average (46 vs. 45). Most of the patients of group 1 and 2 belong in 1st and 2nd functional stage according to Steinbrocker. Average value of morning stiffness for group 1 and 2 was (69.5 vs. 73 minutes) in the beginning of treatment, while in the end of the treatment was (26 vs. 21minutes, p
rheumatoid arthritis; DMARDs